TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
-
- STATUS
- Recruiting
-
- days left to enroll
- 5
-
- participants needed
- 140
-
- sponsor
- National Cancer Institute (NCI)
Summary
- Background
-
- TRC102 is a new cancer treatment drug that may help improve the results of chemotherapy. It
blocks tumor cells' attempts to repair damaged DNA, which may allow chemotherapy to kill the
cells more easily. Researchers want to see how well it works with temozolomide, a
chemotherapy drug that is designed to damage tumor cell DNA. These drugs will be given to
people who have advanced solid tumors or lymphomas that have not responded to earlier
treatments.
- Objectives
- To test the safety and effectiveness of TRC102 and temozolomide for advanced solid tumors
and lymphomas.
- Eligibility
- Individuals at least 18 years of age who have advanced solid tumors or lymphomas that have
not responded to earlier treatments.
- Design
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor samples may also be collected. The size and location of the tumors will be determined with imaging studies.
- Participants will take TRC102 and temozolomide for 28-day cycles of treatment. They will take temozolomide and TRC 102 by mouth once a day on days 1-5. Participants will keep a diary to record doses and any side effects.
- Treatment will be monitored with frequent blood tests and imaging studies. Tumor samples will also be collected.
- Participants will continue their treatment as long as the cancer does not grow and there are no severe side effects.
- TRC102 is a new cancer treatment drug that may help improve the results of chemotherapy. It
blocks tumor cells' attempts to repair damaged DNA, which may allow chemotherapy to kill the
cells more easily. Researchers want to see how well it works with temozolomide, a
chemotherapy drug that is designed to damage tumor cell DNA. These drugs will be given to
people who have advanced solid tumors or lymphomas that have not responded to earlier
treatments.
Description
- Background
-Base excision repair (BER) of DNA repair pathway has been implicated in resistance to
both alkylating and antimetabolite chemotherapy.
-TRC102 (methoxyamine HCl) acts through a novel mechanism to inhibit BER and has
demonstrated the ability to potentiate the activity of the alkylating agent temozolomide
(TMZ), in vitro and in vivo. We hypothesize that TRC102 can be safely co-administered
with TMZ and would potentiate DNA damage caused by TMZ, resulting in antitumor
responses.
-Based on responses measured during the Phase I portion of the trial, we will further
explore the efficacy of this combination in patients with metastatic colon carcinoma, nonsmall
cell lung cancer (NSCLC), and granulosa cell ovarian cancer
Primary Objective:
-To establish the safety, tolerability, and maximum tolerated dose (MTD) of oral TRC102
in combination with oral TMZ in patients with refractory solid tumors
-Evaluate the pharmacokinetic (PK) profile of oral TRC102 when administered in
combination with TMZ.
-To explore the response rate of this combination in patients with colon cancer, NSCLC,
and granulosa cell ovarian cancer
Secondary Objective:
- To explore the progression free survival rate of this combination in patients with colon
cancer, NSCLC, and granulosa cell ovarian cancer
Exploratory Objectives:
- Investigate tumor genomic and transcriptomic alterations potentially associated with sensitivity and/or the development of resistance to TRC102 and temozolomide.
- Determine the effects of the study treatment on the level of histone gamma-H2AX in circulating tumor cells (CTCs) and tumor and correlate the gamma-H2AX response in tumor and CTCs
- Determine the effects of the study treatment on the levels of cleaved caspase 3, epithelial- mesenchymal transition, and APE in tumor and CTCs
- Determine and characterize the effects of study treatment on erythrocytes
- Characterize the clinical presentation of hemolysis observed in earlier study subjects
and explore the possible mechanisms
- Eligibility
-Phase I: histologically confirmed solid tumors that have progressed on standard therapy
known to prolong survival or for which no standard treatment options exist
-Phase II: histologically confirmed adenocarcinoma of the colon post at least two lines of
therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at
least one line of therapy
- No major surgery, radiation, or chemotherapy within 4 weeks prior to entering the study
- Adequate organ function
- Healthy adult volunteers greater than or equal to 18 years of age will be consented to donate research blood
Please note: healthy adult volunteers will no longer be recruited to provide blood for this study as we will no longer perform the hemolysis analysis.
Study Design: Phase I
- This is an open-label Phase I trial; traditional 3+3 design.
- Oral TRC102 and oral TMZ will be administered daily, days 1-5 in 28-day cycles
- Once the MTD is established, up to 15 additional patients will be enrolled at the MTD to
further evaluate that dose for PK and PD endpoints for evidence of DNA damage and
apoptosis.
-During the escalation phase, tumor biopsies will be optional. During the expansion phase,
(once MTD is reached), mandatory paired tumor biopsies will be pursued in the 15
additional patients enrolled to further evaluate PD endpoints.
Phase II
-This is a 3-arm Simon 2-stage design trial evaluating independently the response rate of
patients with colon, NSCLC, and granulosa cell ovarian cancer.
- Patients with a body surface area (BSA) of greater than or equal to 1.6 m(2) will receive 125 mg of TRC 102 and 150 mg/m2 of TMZ PO qday x 5 every 28 days (DL6). Patients with a BSA of <1.6 m(2) will receive 100 mg of TRC 102 and 150 mg/m2 of TMZ PO qday x 5 every 28 days (DL5).. Each cycle will be 28 days.
- The accrual ceiling for the Phase II portion is 75 patients.
- Mandatory paired tumor biopsies will be pursued to further evaluate PD endpoints.
Details
| Condition | Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer |
|---|---|
| Treatment | TRC 102 |
| Clinical Study Identifier | NCT01851369 |
| Sponsor | National Cancer Institute (NCI) |
| Last Modified on | 4 October 2022 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer